Top of the Class

'Tis the season of graduations, even for autism drugs.About a year ago, a small biotech company announced that one of its compounds improved social behaviors in a group of 15 children with fragile X syndrome. Last week, the drug matriculated to a phase-3 trial — the last and most difficult step on the long road to regulatory approval.Read more at...SFARI, June 2011.